Yıl: 2016 Cilt: 48 Sayı: 2 Sayfa Aralığı: 135 - 141 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022

Bir Melatonin Derlemesi, Reseptörleri ve İlaçları

Öz:
Saat genlerini anlamamıza olan katkısından dolayı bir Türk bilim adamı Nobel ödülünü aldıktan sonra, bu genlerle yakın ilişkili olan melatoninin önemi arttı. Melatonin, pineal bezden gece salınan bir hormondur, uyku/uyanıklık döngüsünde, pubertal gelişimde ve mevsimsel adaptasyonda rol alır. Melatoninin antinosiseptif, antidepresan, anksiyolitik, antineofobik, locomotor aktiviteyi düzenleyici, nöroprotektif, antiinflamatuvar, ağrı düzenleyici, kan basıncını düşürücü, retinal, vasküler, tümör baskılayıcı ve antioksidan etkileri vardır. Hafıza, over fizyolojisi ve osteoblast diferansiasyonuyla ilişkilidir. Melatonin seviyelerinde artış veya azalışla seyreden patolojiler derlemede özetlenmiştir. Melatonin 4 mekanizmayla etkir: 1) Plazma membranında melatonin reseptörlerine bağlanma, 2) Kalmodulin gibi hücre içi reseptörlere bağlanma, 3) Yetim nükleer reseptörlere bağlanma, 4) Antioksidan etkiler. Melatoninle ilişkili reseptörler şunlardır: 1) Melatonin reseptör tip1a: MT1 (hücre zarında), 2) Melatonin reseptör tip1b: MT2 (hücre zarında), 3) Melatonin reseptör tip1c (balık, amfibiler ve kuşlarda bulunur), 4) Kuinon redüktaz-2 enzimi (MT3 reseptörü, bir detoksifikasyon enzimi), 5) RZR/ROR?: Retinoid-ilişkili Yetim çekirdek hormon reseptörü (bu reseptörle melatonin çekirdekte transkripsiyon faktörlerine bağlanır), 6) GPR50: X-geçişli Melatonin-ilişkili yetim reseptör (melatoninin MT1'e bağlanmasında etkilidir). Ramelteon, agomelatin, sirkadin, TIK-301 and tasimelteon gibi Melatonin agonistleri tanıtılacak ve yan etkileri karşılaştırılacaktır. Sonuçta, melatonin ve ilişkili ilaçlar tıpta yeni ve umut vaat eden bir alandır. Melatonin reseptörleri ve ilaçları gelecekte de artan oranda ilgi çekmeye devam edecektir.
Anahtar Kelime:

Konular: Genel ve Dahili Tıp

A Review of Melatonin, Its Receptors and Drugs

Öz:
After a Turkish scientist took Nobel Prize due to his contributions to understand clock genes, melatonin, closely related to these genes, may begin to shine. Melatonin, a hormone secreted from the pineal gland at night, plays roles in regulating sleep-wake cycle, pubertal development and seasonal adaptation. Melatonin has antinociceptive, antidepressant, anxiolytic, antineophobic, locomotor activityregulating, neuroprotective, anti-inflammatory, pain-modulating, blood pressure-reducing, retinal, vascular, anti-tumor and antioxidant effects. It is related with memory, ovarian physiology, and osteoblast differentiation. Pathologies associated with an increase or decrease in melatonin levels are summarized in the review. Melatonin affects by four mechanisms: 1) Binding to melatonin receptors in plasma membrane, 2) Binding to intracellular proteins such as calmoduline, 3) Binding to Orphan nuclear receptors, and 4) Antioxidant effect. Receptors associated with melatonin are as follows: 1) Melatonin receptor type 1a: MT1 (on cell membrane), 2) Melatonin receptor type 1b: MT2 (on cell membrane), 3) Melatonin receptor type 1c (found in fish, amphibians and birds), 4) Quinone reductase 2 enzyme (MT3 receptor, a detoxification enzyme), 5) RZR/ROR?: Retinoid-related Orphan nuclear hormone receptor (with this receptor, melatonin binds to the transcription factors in nucleus), and 6) GPR50: X-linked Melatonin-related Orphan receptor (it is effective in binding of melatonin to MT1). Melatonin agonists such as ramelteon, agomelatine, circadin, TIK-301 and tasimelteon are introduced and side effects will be discussed. In conclusion, melatonin and related drugs is a new and promising era for medicine. Melatonin receptors and melatonin drugs will take attention with greater interest day by day in the future.
Anahtar Kelime:

Konular: Genel ve Dahili Tıp
Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1. Pandi-Perumal SR, Trakht I, Srinivasan V, et al. Physiological effects of melatonin: role of melatonin receptors and signal transduction pathways. Prog Neurobiol 2008; 85: 335-53. [CrossRef]
  • 2. Comai S, Gobbi G. Unveiling the role of melatonin MT2 receptors in sleep, anxiety and other neuropsychiatric diseases: a novel target in psychopharmacology. J Psychiatry Neurosci 2014; 39: 6-21. [CrossRef]
  • 3. Uz T, Arslan AD, Kurtuncu M, et al. The regional and cellular expression profile of the melatonin receptor MT1 in the central dopaminergic system. Brain Res Mol Brain Res 2005; 136: 45-53. [CrossRef]
  • 4. Li DY, Smith DG, Hardeland R, et al. Melatonin receptor genes in vertebrates. Int J Mol Sci 2013; 14: 11208-23. [CrossRef]
  • 5. Bondy SC, Sharman EH. Melatonin and the aging brain. Neurochem Int 2007; 50: 571-80. [CrossRef]
  • 6. Fauteck J, Schmidt H, Lerchl A, et al. Melatonin in epilepsy: first results of replacement therapy and first clinical results. Biol Signals Recept 1999; 8: 105-10. [CrossRef]
  • 7. Genell H. Melatonin and the pineal gland. Journal of Neuroscience Nursing 2002; 34: 74-8. [CrossRef]
  • 8. Dubocovich ML, Rivera-Bermudez MA, Gerdin MJ, Masana MI: Molecular pharmacology, regulation and function of mammalian melatonin receptors. Front Biosci 2003; 8: d1093-1108. [CrossRef]
  • 9. Carlberg C. Gene regulation by melatonin. Ann N Y Acad Sci 2000; 917: 387-96. [CrossRef]
  • 10. Thomas B, Mohanakumar KP. Melatonin protects against oxidative stress caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the mouse nigrostriatum. J Pineal Res 2004; 36: 25-32. [CrossRef]
  • 11. Srinivasan V, Pandi-Perumal SR, Cardinali DP, Poeggeler B, Hardeland R. Melatonin in Alzheimer's disease and other neurodegenerative disorders. Behav Brain Funct 2006; 2: 15. [CrossRef]
  • 12. Dehghan F, Khaksari Hadad M, Asadikram G, Najafipour H, Shahrokhi N. Effect of melatonin on intracranial pressure and brain edema following traumatic brain injury: role of oxidative stresses. Arch Med Res 2013; 44: 251-8. [CrossRef]
  • 13. Baydas G, Yasar A, Tuzcu M. Comparison of the impact of melatonin on chronic ethanol-induced learning and memory impairment between young and aged rats. J Pineal Res 2005; 39: 346-52. [CrossRef]
  • 14. Weil ZM, Hotchkiss AK, Gatien ML, Pieke-Dahl S, Nelson RJ. Melatonin receptor (MT1) knockout mice display depressionlike behaviors and deficits in sensorimotor gating. Brain Res Bull 2006; 68: 425-9. [CrossRef]
  • 15. Lee EJ, Lee MY, Chen HY, et al. Melatonin attenuates gray and white matter damage in a mouse model of transient focal cerebral ischemia. J Pineal Res 2005; 38: 42-52. [CrossRef]
  • 16. Baydas G, Ozer M, Yasar A, Tuzcu M, Koz ST. Melatonin improves learning and memory performances impaired by hyperhomocysteinemia in rats. Brain Res 2005; 1046(1-2): 187-94. [CrossRef]
  • 17. Martin V, Herrera F, Carrera-Gonzalez P, et al. Intracellular signaling pathways involved in the cell growth inhibition of glioma cells by melatonin. Cancer Res 2006; 66: 1081-8. [CrossRef]
  • 18. Martinez-Cruz F, Osuna C, Guerrero JM. Mitochondrial damage induced by fetal hyperphenylalaninemia in the rat brain and liver: its prevention by melatonin, Vitamin E, and Vitamin C. Neurosci Lett 2006; 392: 1-4. [CrossRef]
  • 19. Di Carlo M, Giacomazza D, San Biagio PL: Alzheimer's disease: biological aspects, therapeutic perspectives and diagnostic tools. J Phys Condens Matter 2012; 24: 244102. [CrossRef]
  • 20. Poeggeler B, Miravalle L, Zagorski MG, et al. Melatonin reverses the profibrillogenic activity of apolipoprotein E4 on the Alzheimer amyloid Abeta peptide. Biochemistry 2001; 40: 14995-5001. [CrossRef]
  • 21. Ekmekcioglu C. Melatonin receptors in humans: biological role and clinical relevance. Biomed Pharmacother 2006; 60: 97-108. [CrossRef]
  • 22. Kunz D, Schmitz S, Mahlberg R, et al. A new concept for melatonin deficit: on pineal calcification and melatonin excretion. Neuropsychopharmacology 1999; 21: 765-72. [CrossRef]
  • 23. Lipton J, Megerian JT, Kothare SV, et al. Melatonin deficiency and disrupted circadian rhythms in pediatric survivors of craniopharyngioma. Neurology 2009; 73: 323-5. [CrossRef]
  • 24. Hardeland R. Melatonin in aging and disease -multiple consequences of reduced secretion, options and limits of treatment. Aging Dis 2012; 3: 194-225.
  • 25. van der Helm-van Mil AH, van Someren EJ, van den Boom R, et al. No influence of melatonin on cerebral blood flow in humans. J Clin Endocrinol Metab 2003; 88: 5989-94. [CrossRef]
  • 26. Krauchi K, Cajochen C, Wirz-Justice A. A relationship between heat loss and sleepiness: effects of postural change and melatonin administration. J Appl Physiol (1985) 1997; 83: 134-9.
  • 27. van den Heuvel CJ, Kennaway DJ, Dawson D. Thermoregulatory and soporific effects of very low dose melatonin injection. Am J Physiol 1999; 276: E249-54.
  • 28. Chaste P, Clement N, Botros HG, et al. Genetic variations of the melatonin pathway in patients with attention-deficit and hyperactivity disorders. J Pineal Res 2011; 51: 394-9. [CrossRef]
  • 29. Levoye A, Dam J, Ayoub MA, et al. The orphan GPR50 receptor specifically inhibits MT1 melatonin receptor function through heterodimerization. EMBO J 2006; 25: 3012-23. [CrossRef]
  • 30. Rada JA, Wiechmann AF. Melatonin receptors in chick ocular tissues: implications for a role of melatonin in ocular growth regulation. Invest Ophthalmol Vis Sci 2006; 47: 25-33. [CrossRef]
  • 31. Dufourny L, Levasseur A, Migaud M, et al. GPR50 is the mammalian ortholog of Mel1c: evidence of rapid evolution in mammals. BMC Evol Biol 2008; 8: 105. [CrossRef]
  • 32. Hirsch-Rodriguez E, Imbesi M, Manev R, Uz T, Manev H. The pattern of melatonin receptor expression in the brain may influence antidepressant treatment. Med Hypotheses 2007; 69: 120-4. [CrossRef]
  • 33. Gubitz AK, Reppert SM. Assignment of the melatonin-related receptor to human chromosome X (GPR50) and mouse chromosome X (Gpr50). Genomics 1999; 55: 248-51. [CrossRef]
  • 34. Thomson PA, Wray NR, Thomson AM, et al. Sex-specific association between bipolar affective disorder in women and GPR50, an X-linked orphan G protein-coupled receptor. Mol Psychiatry 2005; 10: 470-8. [CrossRef]
  • 35. Chaste P, Clement N, Mercati O, et al. Identification of pathwaybiased and deleterious melatonin receptor mutants in autism spectrum disorders and in the general population. PLoS One 2010; 5: e11495. [CrossRef]
  • 36. Grunewald E, Kinnell HL, Porteous DJ, Thomson PA. GPR50 interacts with neuronal NOGO-A and affects neurite outgrowth. Mol Cell Neurosci 2009; 42: 363-71. [CrossRef]
  • 37. Li J, Hand LE, Meng QJ, Loudon AS, Bechtold DA. GPR50 interacts with TIP60 to modulate glucocorticoid receptor signalling. PLoS One 2011; 6: e23725. [CrossRef]
  • 38. Forrest CM, Mackay GM, Stoy N, Stone TW, Darlington LG. Inflammatory status and kynurenine metabolism in rheumatoid arthritis treated with melatonin. Br J Clin Pharmacol 2007; 64: 517-26. [CrossRef]
  • 39. Pandi-Perumal SR, Srinivasan V, Poeggeler B, Hardeland R, Cardinali DP. Drug Insight: the use of melatonergic agonists for the treatment of insomnia-focus on ramelteon. Nat Clin Pract Neurol 2007; 3: 221-8. [CrossRef]
  • 40. McGechan A, Wellington K. Ramelteon. CNS Drugs 2005; 19: 1057-1065; discussion 1066-1057.
  • 41. Karim A, Tolbert D, Cao C. Disposition kinetics and tolerance of escalating single doses of ramelteon, a high-affinity MT1 and MT2 melatonin receptor agonist indicated for treatment of insomnia. J Clin Pharmacol 2006; 46: 140-8. [CrossRef]
  • 42. Pandi-Perumal SR, Spence DW, Verster JC, et al. Pharmacotherapy of insomnia with ramelteon: safety, efficacy and clinical applications. J Cent Nerv Syst Dis 2011; 3: 51-65.
  • 43. Hardeland R. New approaches in the management of insomnia: weighing the advantages of prolonged-release melatonin and synthetic melatoninergic agonists. Neuropsychiatr Dis Treat 2009; 5: 341-54. [CrossRef]
  • 44. de Bodinat C, Guardiola-Lemaitre B, Mocaer E, Renard P, Munoz C, Millan MJ. Agomelatine, the first melatonergic antidepressant: discovery, characterization and development. Nature reviews Drug discovery 2010; 9: 628-42. [CrossRef]
  • 45. Lewy AJ, Lefler BJ, Emens JS, Bauer VK. The circadian basis of winter depression. Proc Natl Acad Sci U S A 2006; 103: 7414-9. [CrossRef]
  • 46. Millan MJ, Gobert A, Lejeune F, et al. The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J Pharmacol Exp Ther 2003; 306: 954-64. [CrossRef]
  • 47. Weishaupt JH, Bartels C, Polking E, et al. Reduced oxidative damage in ALS by high-dose enteral melatonin treatment. J Pineal Res 2006; 41: 313-23. [CrossRef]
  • 48. Claustrat B, Brun J, Chazot G. The basic physiology and pathophysiology of melatonin. Sleep Med Rev 2005; 9: 11-24. [CrossRef]
  • 49. Landolt HP, Wehrle R. Antagonism of serotonergic 5-HT2A/2C receptors: mutual improvement of sleep, cognition and mood? Eur J Neurosci 2009; 29: 1795-809. [CrossRef]
  • 50. Mulchahey JJ, Goldwater DR, Zemlan FP. A single blind, placebo controlled, across groups dose escalation study of the safety, tolerability, pharmacokinetics and pharmacodynamics of the melatonin analog beta-methyl-6-chloromelatonin. Life Sci 2004; 75: 1843-56. [CrossRef]
  • 51. Hardeland R, Poeggeler B, Srinivasan V, Trakht I, Pandi-Perumal SR, Cardinali DP. Melatonergic drugs in clinical practice. Arzneimittelforschung 2008; 58: 1-10.
  • 52. Agomelatine: new drug. Adverse effects and no proven efficacy. Prescrire Int 2009; 18: 241-45.
  • 53. Costello RB, Lentino CV, Boyd CC, et al. The effectiveness of melatonin for promoting healthy sleep: a rapid evidence assessment of the literature. Nutrition journal 2014; 13: 106. [CrossRef]
  • 54. Ferry G, Hecht S, Berger S, et al. Old and new inhibitors of quinone reductase 2. Chem Biol Interact 2010; 186: 103-9. [CrossRef]
  • 55. Manev H, Uz T. Clock genes: influencing and being influenced by psychoactive drugs. Trends Pharmacol Sci 2006; 27: p. 186-9. [CrossRef]
APA EMET M, Özcan H, ÖZEL L, Yayla M, HALICI Z, Hacimuftuoglu A (2016). Bir Melatonin Derlemesi, Reseptörleri ve İlaçları. , 135 - 141.
Chicago EMET Mücahit,Özcan Halil,ÖZEL Lütfü,Yayla Muhammed,HALICI Zekai,Hacimuftuoglu Ahmet Bir Melatonin Derlemesi, Reseptörleri ve İlaçları. (2016): 135 - 141.
MLA EMET Mücahit,Özcan Halil,ÖZEL Lütfü,Yayla Muhammed,HALICI Zekai,Hacimuftuoglu Ahmet Bir Melatonin Derlemesi, Reseptörleri ve İlaçları. , 2016, ss.135 - 141.
AMA EMET M,Özcan H,ÖZEL L,Yayla M,HALICI Z,Hacimuftuoglu A Bir Melatonin Derlemesi, Reseptörleri ve İlaçları. . 2016; 135 - 141.
Vancouver EMET M,Özcan H,ÖZEL L,Yayla M,HALICI Z,Hacimuftuoglu A Bir Melatonin Derlemesi, Reseptörleri ve İlaçları. . 2016; 135 - 141.
IEEE EMET M,Özcan H,ÖZEL L,Yayla M,HALICI Z,Hacimuftuoglu A "Bir Melatonin Derlemesi, Reseptörleri ve İlaçları." , ss.135 - 141, 2016.
ISNAD EMET, Mücahit vd. "Bir Melatonin Derlemesi, Reseptörleri ve İlaçları". (2016), 135-141.
APA EMET M, Özcan H, ÖZEL L, Yayla M, HALICI Z, Hacimuftuoglu A (2016). Bir Melatonin Derlemesi, Reseptörleri ve İlaçları. Eurasian Journal of Medicine, 48(2), 135 - 141.
Chicago EMET Mücahit,Özcan Halil,ÖZEL Lütfü,Yayla Muhammed,HALICI Zekai,Hacimuftuoglu Ahmet Bir Melatonin Derlemesi, Reseptörleri ve İlaçları. Eurasian Journal of Medicine 48, no.2 (2016): 135 - 141.
MLA EMET Mücahit,Özcan Halil,ÖZEL Lütfü,Yayla Muhammed,HALICI Zekai,Hacimuftuoglu Ahmet Bir Melatonin Derlemesi, Reseptörleri ve İlaçları. Eurasian Journal of Medicine, vol.48, no.2, 2016, ss.135 - 141.
AMA EMET M,Özcan H,ÖZEL L,Yayla M,HALICI Z,Hacimuftuoglu A Bir Melatonin Derlemesi, Reseptörleri ve İlaçları. Eurasian Journal of Medicine. 2016; 48(2): 135 - 141.
Vancouver EMET M,Özcan H,ÖZEL L,Yayla M,HALICI Z,Hacimuftuoglu A Bir Melatonin Derlemesi, Reseptörleri ve İlaçları. Eurasian Journal of Medicine. 2016; 48(2): 135 - 141.
IEEE EMET M,Özcan H,ÖZEL L,Yayla M,HALICI Z,Hacimuftuoglu A "Bir Melatonin Derlemesi, Reseptörleri ve İlaçları." Eurasian Journal of Medicine, 48, ss.135 - 141, 2016.
ISNAD EMET, Mücahit vd. "Bir Melatonin Derlemesi, Reseptörleri ve İlaçları". Eurasian Journal of Medicine 48/2 (2016), 135-141.